mRNA-4157/V940 Research for Melanoma (Adjuvant)
An evidence-based overview of research examining mRNA-4157/V940 in the context of melanoma (adjuvant). This page synthesizes findings from peer-reviewed literature.
Research Summary
mRNA-4157 in combination with pembrolizumab is being developed as adjuvant therapy for resected high-risk melanoma. KEYNOTE-942 Phase 2b trial demonstrated 44% reduction in recurrence or death. FDA granted Breakthrough Therapy Designation in 2023. Phase 3 INTerpath-001 trial ongoing with ~1,100 patients.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. mRNA-4157/V940 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.